Related Experiment Video
Updated: Mar 5, 2026
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
Published on: January 7, 2019
Associations Between Medication Class and Subsequent Augmentation of Depression Treatment in Privately Insured US
Omid Ameli1, Rene Soria-Saucedo, Eric G Smith
1From the *Boston University School of Public Health, and †Boston University School of Public Health, Health Law Policy and Management Department, Boston; ‡Center for Healthcare Organization and Implementation Research, Edith Nourse Rogers Memorial Veterans Hospital, Bedford; §Department of Psychiatry, University of Massachusetts Medical School, Worcester; ∥Department of Biostatistics, Boston University School of Public Health, and ¶Center for the Assessment of Pharmaceutical Practices, Boston University School of Public Health, Boston, MA.
Importance:
Treatment augmentation is an important clinical decision in the pharmacotherapy for depression, yet few studies have examined the rates of treatment augmentation by medication class.
Objective:
The aim of this study was to examine which initial pharmacotherapies for depression are more likely than others to result in subsequent treatment augmentation.
Methods:
This study is a retrospective cohort analysis of administrative data of 214,705 privately insured US adults between the age of 18 and 64 years who were diagnosed with a new episode of depression in 2009. Propensity score-adjusted logistic regression and Cox regression were used to model the effect of the class of initial monotherapy on treatment augmentation. Risk adjustors included depression severity, comorbidities, provider type, insurance, and demographic characteristics.
Exposure:
The class of initial monotherapy and the health care provider type were the main independent variables of interest.
Main Outcome:
The outcome was the augmentation of monotherapy.
Results:
Thirty-four percent of individuals received treatment augmentation. Compared with selective serotonin reuptake inhibitor monotherapy, second-generation antipsychotics as the initial treatment were associated with significant increase in the likelihood of augmentation compared with the other classes (hazards ratio, 2.59; 95% confidence interval [CI], 2.51-2.68). This result was corroborated after propensity score adjustment (odds ratio, 2.85; 95% CI, 2.70-3.00) when comparing second-generation antipsychotics to the other classes of pharmacotherapy. The other significant predictor of treatment augmentation was the provider type. Mental health specialists were 27% more likely to augment a treatment compared with generalists (hazards ratio, 1.27; 95% CI, 1.25-1.30).
Conclusions:
The type of initial antidepressant therapy is associated with the chances of treatment augmentation. Second-generation antipsychotics progressed to augmentation more rapidly than the other classes.
More Related Videos
04:33Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
Published on: April 26, 2024
08:15Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
Related Concept Videos
01:23Antidepressant Drugs: MAOIs and Other Agents
01:25Antidepressant Drugs: Overview
01:28Drug Therapy
Antianxiety Medications
01:54The Placebo Effect
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
01:27Depressive Disorders: Etiology
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...